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1. Introduction {#jia225194-sec-0005}
===============

Routine viral load (VL) monitoring is the most important tool for assessing a patient\'s response to treatment, and assessing adherence to antiretroviral therapy (ART). The World Health Organization (WHO) recommends a VL test six and twelve months after starting ART and every twelve months thereafter [1](#jia225194-bib-0001){ref-type="ref"}, [2](#jia225194-bib-0002){ref-type="ref"}. For patients with elevated VLs (\>1000 copies/mL), enhanced adherence counselling (EAC) is provided to identify adherence barriers. Virological failure is established if the next VL, taken between three and six months later, remains elevated [1](#jia225194-bib-0001){ref-type="ref"}. Clinicians should then switch treatment. Delaying treatment switching leads to accumulation of resistance mutations [3](#jia225194-bib-0003){ref-type="ref"}, [4](#jia225194-bib-0004){ref-type="ref"}, [5](#jia225194-bib-0005){ref-type="ref"}, unfavourable patient outcomes and increased risk of transmission of drug‐resistant strains [6](#jia225194-bib-0006){ref-type="ref"}, [7](#jia225194-bib-0007){ref-type="ref"}, [8](#jia225194-bib-0008){ref-type="ref"}, [9](#jia225194-bib-0009){ref-type="ref"}, [10](#jia225194-bib-0010){ref-type="ref"}, [11](#jia225194-bib-0011){ref-type="ref"}, [12](#jia225194-bib-0012){ref-type="ref"}, [13](#jia225194-bib-0013){ref-type="ref"}, [14](#jia225194-bib-0014){ref-type="ref"}, [15](#jia225194-bib-0015){ref-type="ref"}, [16](#jia225194-bib-0016){ref-type="ref"}, [17](#jia225194-bib-0017){ref-type="ref"}, [18](#jia225194-bib-0018){ref-type="ref"}, [19](#jia225194-bib-0019){ref-type="ref"}, [20](#jia225194-bib-0020){ref-type="ref"}, [21](#jia225194-bib-0021){ref-type="ref"}. If the second consecutive VL is re‐suppressed, patients usually remain on the same treatment regimen assuming that treatment adherence is restored without major drug resistance (DR).

Resource‐limited settings are scaling up routine VL monitoring. However, VL demonstration projects reported programmatic shortfalls and variability in quality of care along the VL cascade [22](#jia225194-bib-0022){ref-type="ref"}, [23](#jia225194-bib-0023){ref-type="ref"}. Other gaps include poorly equipped laboratories, lack of trained laboratory personnel, lack of up‐to‐date testing knowledge and blood sample transportation barriers [24](#jia225194-bib-0024){ref-type="ref"}.

Understanding of the gaps along the VL cascade remains limited but is needed to inform VL scale‐up in resource‐limited settings. We evaluated the performance of the VL cascade in a public health sector programme and describe the ability of the WHO VL testing algorithm to predict the need for treatment switching.

2. Methods {#jia225194-sec-0006}
==========

2.1. Setting {#jia225194-sec-0007}
------------

In Swaziland, 31% of the adult population (aged 18 to 49 years) are HIV positive [25](#jia225194-bib-0025){ref-type="ref"}, [26](#jia225194-bib-0026){ref-type="ref"}. Since 2007, the Swaziland Ministry of Health and Médecins Sans Frontières have provided integrated HIV/tuberculosis care in the rural Shiselweni region (210,000 population), which is served by 23 primary health clinics and three secondary health facilities. In 2012, routine VL monitoring was introduced, serving an estimated ART cohort of 15,000 patients. The HIV programme has been described elsewhere [23](#jia225194-bib-0023){ref-type="ref"}. Briefly, the national treatment guidelines [27](#jia225194-bib-0027){ref-type="ref"} follow WHO recommendations, with routine VL testing performed at six and twelve months after ART initiation, and annually thereafter. A biocentric generic HIV VL platform is used for VL testing. In the case of an elevated VL, an enhanced adherence intervention is triggered to assess and rectify adherence barriers, with the first counselling session occurring at the clinic visit following the elevated VL. Patients receiving a VL test receive a month\'s pill refill, with patients with an elevated VL remaining on a monthly pill refill schedule to facilitate EAC. Patients receive three consecutive counselling sessions over a period of three months facilitated by trained lay counsellors with involvement of nurses and psychologists for complicated cases. These sessions are recorded in a dedicated EAC register and within the patient file. If the subsequent VL is re‐suppressed, patients continue with the same treatment regimen. If the VL remains elevated, medical doctors switch to a second‐line regimen.

2.2. Study population {#jia225194-sec-0008}
---------------------

This retrospective cohort analysis included patients on first‐ and second‐line ART who were aged 18 years or over and had an elevated VL \> 1000 copies/mL [1](#jia225194-bib-0001){ref-type="ref"}, [27](#jia225194-bib-0027){ref-type="ref"} in any of the 23 primary care clinics in the Shiselweni region (Swaziland), between January 2013 and June 2014, and were followed‐up through December 2015. Additionally, the DR cohort included patients from three secondary care facilities that served the same population.

2.3. Patient identification and data extraction {#jia225194-sec-0009}
-----------------------------------------------

Patients with elevated VLs were identified through the laboratory‐based VL database. Clinical, counselling and demographic information were extracted from individual patient files and facility‐based registers.

2.4. HIV DR testing and interpretation {#jia225194-sec-0010}
--------------------------------------

Dried blood spots (DBS) were obtained consecutively from patients with virological failure in the same primary care clinics and from three secondary care facilities between August 2013 and September 2014, and sent to the Centers for Disease Control (Atlanta) for HIV DR testing [28](#jia225194-bib-0028){ref-type="ref"}.

DR mutations were analysed according to the HIVdb Stanford Genotypic Resistance Interpretation Algorithm, and DR was defined as low, intermediate or high resistance against the most commonly used antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTIs) -- zidovudine, lamivudine (3TC), abacavir (ABC), stavudine, didanosine and tenofovir (TDF); non‐nucleoside reverse transcriptase inhibitors (NNRTIs) -- efavirenz (EFV) and nevirapine (NVP); and protease inhibitor (PI): ritonavir‐boosted lopinavir (LPV/r). DR requiring treatment switching was defined as any DR to both EFV and NVP for a patient on first‐line therapy and any LPV/r resistance for a patient on second‐line therapy. Owing to a long turnaround time in receiving the genotype results, the treatment switching decision was based on documented virological failure.

2.5. Variables and definitions {#jia225194-sec-0011}
------------------------------

An elevated VL was defined as a VL \> 1000 copies/mL [1](#jia225194-bib-0001){ref-type="ref"}, [27](#jia225194-bib-0027){ref-type="ref"}, virological failure as two consecutive elevated VLs measurements three months apart, and re‐suppression as a consecutive VL ≤ 1000 copies/mL following an elevated VL.

Patients were followed‐up from the time of first recorded elevated VL until uptake of the second consecutive VL test and from the time of the second elevated VL test to treatment switching in time‐to‐event analysis. Censoring occurred at the date of last clinic visit for patients lost to follow‐up (LTFU) at the facility (three months without a recorded clinic visit) or at the end of the observation period on 31 December 2015.

EAC was assumed to have been done if the adherence session was recorded in the patient\'s file or in the facility‐based EAC register.

2.6. Statistical analysis {#jia225194-sec-0012}
-------------------------

We calculated counts and proportions of patients at every level of the cascade. A Pearson\'s chi‐square test was used to compare categorical variables, and the Kruskal--Wallis test was used for comparison of continuous variables. We used Kaplan--Meier survival curves to estimate cumulative probabilities of receiving a follow‐up VL test. LTFU was treated as a competing risk for switching to second‐line therapy after two consecutive elevated VLs. A Fine and Gray proportional subdistribution hazards model [29](#jia225194-bib-0029){ref-type="ref"} was used to determine the factors associated with treatment switching in the presence of LTFU as a competing risk. We used logistic regression to determine the factors associated with VL re‐suppression following an elevated VL, using variables that had been shown to be associated with re‐suppression in previous studies [30](#jia225194-bib-0030){ref-type="ref"}, [31](#jia225194-bib-0031){ref-type="ref"}, [32](#jia225194-bib-0032){ref-type="ref"}, [33](#jia225194-bib-0033){ref-type="ref"}, [34](#jia225194-bib-0034){ref-type="ref"}, [35](#jia225194-bib-0035){ref-type="ref"}, [36](#jia225194-bib-0036){ref-type="ref"}. A parsimonious model was achieved using Wald tests and likelihood ratio tests. For patients who were LTFU and did not have a second VL result, we performed a sensitivity analysis looking at two extreme cases (where all re‐suppressed or none re‐suppressed) to assess the robustness of our findings. We also used a logistic regression model for the odds of LTFU versus completion of the study.

DR was determined for each individual first‐ and second‐line drug. Patients on first‐line therapy were considered eligible for switching (according to the genotype resistance testing results) if they had developed high‐, intermediate‐ or low‐level resistance to both NNRTIs (NVP and EFV), as were those on second‐line therapy if they had developed resistance to LPV/r. We calculated the positive predictive value (PPV) of the WHO treatment‐switching algorithm by using the number of people with genuine resistance requiring treatment switching over the total number of patients who received a genotype.

Statistical analysis was performed with STATA 14.1 [37](#jia225194-bib-0037){ref-type="ref"}.

2.7. Ethics {#jia225194-sec-0013}
-----------

Ethics approval was obtained from the MSF Ethics Review Board and the Scientific and Ethics Committee of the Ministry of Health of Swaziland.

3. Results and Discussion {#jia225194-sec-0014}
=========================

3.1. Baseline characteristics {#jia225194-sec-0015}
-----------------------------

A total of 828 patients (Table [1](#jia225194-tbl-0001){ref-type="table"}) had at least one elevated VL recorded between January 2013 and June 2014. The median age was 35 years (interquartile range (IQR): 29, 44), and 542 (65.5%) patients were female. The median time on ART was 2.95 (IQR: 1.81, 4.31) years, 820 (99.0%) patients were on first‐line ART and the most common first‐line regimen was TDF/3TC/EFV (n = 330; 39.9%).

###### 

Baseline characteristics of patients with an elevated VL who received a follow‐up VL, their VL outcomes and factors associated with VL re‐suppression (\<1000 copies/mL) at second VL test done

                               First VL elevated (VL \> 1000 copies/mL), n (%)   Follow‐up VL done, n (%)       VL suppressed (\<1000 copies/mL), n (%)   cOR (95% CI)          *p* value   aOR (95% CI) (n = 695)   *p* value
  ---------------------------- ------------------------------------------------- ------------------------------ ----------------------------------------- --------------------- ----------- ------------------------ -----------
  Total                        828                                               696 (84.1%)                    410 (49.5%)                                                                                          
  Sex                                                                                                                                                                                                                
  Female                       542 (65.5)                                        451 (64.8)                     265 (64.6)                                Reference             \_\_                                 
  Male                         286 (34.5)                                        245 (35.2)                     145 (35.4)                                1.02 (0.74 to 1.40)   0.913                                
  Baseline regimen (n = 703)                                                                                                                                                                                         
  AZT/3TC/NVP                  222 (26.8)                                        194 (27.9)                     103 (25.1)                                Reference             \_\_                                 
  AZT/3TC/EFV                  58 (7)                                            51 (7.3)                       31 (7.6)                                  1.37 (0.73 to 2.57)   0.327                                
  TDF/3TC/NVP                  14 (1.7)                                          12 (1.7)                       7 (1.7)                                   1.24 (0.38 to 4.03)   0.724                                
  TDF/3TC/EFV                  330 (39.9)                                        275 (39.5                      169 (41.2)                                1.41 (0.97 to 2.04)   0.071                                
  D4T/3TC/NVP                  58 (7)                                            51 (7.3)                       31 (7.6)                                  1.37 (0.73 to 2.57)   0.327                                
  D4T/3TC/EFV                  18 (2.2)                                          17 (2.4)                       8 (1.9)                                   0.79 (0.29 to 2.12)   0.633                                
  ABC/3TC/NVP                  1 (0.1)                                           1 (0.1)                        0 (0)                                     \_\_                  \_\_                                 
  ABC/3TC/EFV                  2 (0.2)                                           2 (0.3)                        2 (0.5)                                   \_\_                  \_\_                                 
  Missing                      125 (15.1)                                        93 (13.4)                      59 (14.4)                                 \_\_                  \_\_                                 
  Age                                                                                                                                                                                                                
  18 to 34                     398 (48.1)                                        312 (44.8)                     178 (43.4)                                Reference             \_\_        Reference                \_\_
  35 to 49                     304 (36.7)                                        276 (39.7)                     157 (38.3)                                0.99 (0.72 to 1.38)   0.967       1.01 (0.72 to 1.40)      0.964
  50 to 64                     94 (11.4)                                         82 (11.8)                      59 (14.4)                                 1.93 (1.14 to 3.29)   0.015       1.98 (1.16 to 3.40)      0.012
  ≥65                          30 (3.6)                                          25 (3.6)                       16 (3.9)                                  1.34 (0.57 to 3.12)   0.5         1.32 (0.56 to 3.13)      0.52
  Missing                      2 (0.2)                                           1 (0.1)                        0 (0)                                     \_\_                  \_\_        \_\_                     \_\_
  Health zone                                                                                                                                                                                                        
  Nhlangano                    270 (32.6)                                        209 (30.0)                     119 (29)                                  Reference             \_\_                                 
  Hlathikhulu                  288 (34.8)                                        259 (37.2)                     161 (39.3)                                1.24 (0.86 to 1.80)   0.252                                
  Matsanjeni                   270 (32.6)                                        228 (32.8)                     130 (31.7)                                1.00 (0.69 to 1.47)   0.987                                
  EAC                                                                                                                                                                                                                
  Zero sessions                252 (30.4)                                        164 (23.6)                     89 (21.7)                                 Reference             \_\_        Reference                \_\_
  One session                  133 (16.1)                                        116 (16.7)                     68 (16.6)                                 1.19 (0.74 to 1.93)   0.47        1.28 (0.78 to 2.10)      0.319
  Two sessions                 155 (18.7)                                        144 (20.7)                     86 (21)                                   1.25 (0.79 to 1.97)   0.335       1.40 (0.88 to 2.23)      0.152
  Three sessions               288 (34.8)                                        272 (39.1)                     167 (40.7)                                1.34 (0.91 to 1.98)   0.143       1.51 (1.01 to 2.26)      0.045
  Treatment regimen                                                                                                                                                                                                  
  First line                   820 (99)                                          653 (93.8)                     375 (91.5)                                Reference             \_\_        Reference                \_\_
  Second line                  8 (1)                                             43 (6.2)                       35 (8.5)                                  2.87 (1.36 to 6.07)   0.006       3.53 (1.59 to 7.83)      0.002
  Treatment outcome                                                                                                                                                                                                  
  Retained in care             582 (70.3)                                        565 (81.2)                     355 (86.6)                                Reference             \_\_                                 
  LTFU                         246 (29.7)                                        131 (18.8)                     55 (13.4)                                 0.43 (0.29 to 0.63)   \<0.001                              
  Time on ART                  2.95 years (IQR: 1.81, 4.31)                      2.96 years (IQR: 1.86, 4.32)   2.66 years (IQR: 1.73, 4.02)              1 (0.99 to 1.00)      0.161                                

ABC, abacavir; aOR, adjusted odds ratio; ART, antiretroviral therapy; AZT, zidovudine; cOR, crude odds ratio; D4T, stavudine; EAC, enhanced adherence counselling; EFV, efavirenz; IQR, interquartile range; LTFU, lost to follow‐up; NRTI, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; TDF, tenofovir; VL, viral load.

John Wiley & Sons, Ltd

3.2. Lost to follow‐up {#jia225194-sec-0016}
----------------------

Of the 828 patients, 246 (29.7%) were LTFU. The proportion of patients LTFU differed by health zone (*p *=* *0.007), were younger (*p *\< 0.001), more likely to be on first‐line (*p *\< 0.001) and less likely to have received any EAC (*p *\< 0.001) but did not differ by sex or drug regimen. In the multivariable logistic regression, only EAC remained associated with LTFU.

3.3. Enhanced adherence counselling {#jia225194-sec-0017}
-----------------------------------

Of the 828 patients, 252 (30.4%) did not receive EAC, 133 (16.1%) received one session, 155 (18.7%) received two sessions and 288 (34.8%) received all three sessions. The median time from a first elevated VL to the first, second and third EAC session was 42 (IQR: 28, 73), 83 (IQR: 60, 114) and 113 (IQR: 91, 147.5) days respectively.

In our cohort, patients who received EAC were more likely to re‐suppress VL, with an increased likelihood of re‐suppression with each additional EAC session. In total, 84.1% of patients with a first elevated VL received a follow‐up VL of whom 58.9% re‐suppressed.

3.4. VL re‐suppression {#jia225194-sec-0018}
----------------------

Of the 828 patients, 696 (84.1%) received a follow‐up VL test by the end of the observation period. Of the 132 who did not have a follow‐up VL, 115 (87.1%) were LTFU, and 17 (12.9%) were retained on ART. The median time to the follow‐up VL test was 4.6 months (IQR: 3.3, 8.9), and VL test uptake at three and six months were 15.6% (95% CI: 13.3 to 18.3) and 62.1% (95% CI: 58.8 to 65.4).

Compared with findings from the early rollout in this setting [22](#jia225194-bib-0022){ref-type="ref"}, [23](#jia225194-bib-0023){ref-type="ref"}, follow‐up VL testing increased to 84% (vs. 70%) and VL re‐suppression remained similar (59% vs. 62%).

Overall, 410 (58.9%) of the 696 patients with a follow‐up VL had re‐suppressed: 321 (60.3%) of 532 patients who received at least one EAC and 89 (54.3%) of 164 patients without EAC. In multivariable logistic regression (Table [1](#jia225194-tbl-0001){ref-type="table"}), positive predictors of re‐suppression were age 50 to 64 (aOR: 1.98; *p *=* *0.012) compared with age 18 to 34 years and being on second‐line treatment (aOR: 3.53; *p *=* *0.002). The odds of re‐suppression increased with each consecutive EAC compared with patients receiving no intervention, being 1.28 (*p *=* *0.319), 1.40 (*p *=* *0.152) and 1.51 (*p *=* *0.045) for one, two and three EAC sessions. Only second‐line treatment remained significantly associated following sensitivity analysis.

This analysis indicated an increase in VL re‐suppression with each additional EAC session received compared with not receiving counselling. This finding was in contrast to the early rollout, in which EAC did not appear to have an additional benefit [22](#jia225194-bib-0022){ref-type="ref"}. EAC may have become more efficient during the scale‐up of VL testing in terms of messaging, patient support and intensity with proportionally more patients receiving all three EAC sessions.

Age between 50 and 64 years, being on a second‐line regimen and number of EAC sessions were also positive predictors of re‐suppression. Older age has been shown to be a predictor of re‐suppression in other studies [22](#jia225194-bib-0022){ref-type="ref"}, [36](#jia225194-bib-0036){ref-type="ref"} and LPV/r‐based second‐line regimen are known to be more robust [38](#jia225194-bib-0038){ref-type="ref"} as also confirmed by the genotyping results. Patients who received EAC sessions were more likely to re‐suppress, and this showed a dose--response relationship demonstrating the merits of this step in the VL cascade which corresponds with other studies' findings [39](#jia225194-bib-0039){ref-type="ref"}, [40](#jia225194-bib-0040){ref-type="ref"}.

3.5. Treatment switching {#jia225194-sec-0019}
------------------------

Among 278 (39.9%) patients eligible for treatment switching, only 43.2% had their first‐line treatment switched.

Of the 696 patients with a follow‐up VL, 286 (41.1%) had presumptive virological failure. Eight (2.8%) were already on second‐line treatment before the VL result was available, leaving 278 (97.2%) eligible to be switched to a second‐line regimen after virological failure. Overall, 120 (43.2%) had switched by the end of the observation period, and the median time to treatment switching was 5.9 months (IQR: 2.3, 9.9) from the date the result was received back at the facility. Kaplan--Meier estimates showed that 12.6% (95% CI: 9.2 to 17.2) had switched regimens at three months after the date of blood sampling and 22.1% (95% CI: 17.6 to 27.4) had switched at six months.

Thirty‐five patients were switched to second‐line after a single VL \> 1000 copies/mL (median time since VL 35 days, IQR: 24, 63). A review of their VL history showed that 17 patients had an elevated VL at their most recent previous VL test.

In multivariable competing risk regression (Table [2](#jia225194-tbl-0002){ref-type="table"}), an ABC‐based treatment regimen (aHR: 8.58; *p *\< 0.001) was associated with increased probability of treatment switching, but only one patient was in this group. Receiving one, two or three EAC sessions showed a tendency towards increased treatment switching, but this was not statistically significant.

###### 

Baseline characteristics of patients eligible for a treatment switch, their treatment outcomes and factors associated with treatment switching

                              Eligible to be switched to second line (second VL \> 1000 copies/mL), n (%)   Switched to second line, n (%)   cSHR (95% CI)          *p* value   aSHR (n = 219) (95% CI)   *p* value
  --------------------------- ----------------------------------------------------------------------------- -------------------------------- ---------------------- ----------- ------------------------- -----------
  Total                       278                                                                           120 (43.2)                                                                                    
  Sex                                                                                                                                                                                                     
  Female                      179 (64.6)                                                                    78 (65)                          Reference              \_\_                                  
  Male                        99 (35.4)                                                                     42 (35)                          0.95 (0.65 to 1.39)    0.809                                 
  Baseline regimen                                                                                                                                                                                        
  AZT/3TC/NVP                 88 (31.7)                                                                     40 (33.3)                        Reference              \_\_        Reference                 \_\_
  AZT/3TC/EFV                 20 (7.2)                                                                      8 (6.7)                          0.90 (0.43 to 1.91)    0.795       0.94 (0.44 to 1.99)       0.878
  TDF/3TC/NVP                 5 (1.8)                                                                       1 (0.8)                          0.36 (0.05 to 2.49)    0.301       0.36 (0.06 to 2.27)       0.278
  TDF/3TC/EFV                 104 (37.4)                                                                    46 (38.3)                        0.98 (0.64 to 1.48)    0.913       0.97 (0.63 to 1.50)       0.909
  D4T/3TC/NVP                 17 (6.1)                                                                      5 (4.2)                          0.71 (0.28 to 1.78)    0.465       0.76 (0.30 to 1.98)       0.581
  D4T/3TC/EFV                 9 (3.2)                                                                       4 (3.3)                          1.20 (0.40 to 3.54)    0.746       1.05 (0.33 to 3.26)       0.937
  ABC/3TC/NVP                 1 (0.4)                                                                       1 (0.8)                          6.69 (4.44 to 10.06)   \<0.001     8.58 (4.82 to 15.26)      \<0.001
  Missing                     34 (12.2)                                                                     15 (12.5)                        \_\_                                                         
  Age                                                                                                                                                                                                     
  18 to 34                    130 (46.9)                                                                    58 (48.7)                        Reference              \_\_                                  
  35 to 49                    116 (41.5)                                                                    50 (41.2)                        0.91 (0.63 to 1.34)    0.649                                 
  50 to 64                    22 (7.9)                                                                      9 (7.6)                          0.78 (0.39 to 1.54)    0.472                                 
  ≥65                         9 (3.3)                                                                       3 (2.5)                          0.50 (0.16 to 1.52)    0.222                                 
  Missing                     1 (0.4)                                                                       0 (0)                            \_\_                                                         
  Health zone                                                                                                                                                                                             
  Nhlangano                   88 (31.8)                                                                     38 (31.9)                        Reference              \_\_                                  
  Hlathikhulu                 95 (34.3)                                                                     42 (35.3)                        1.46 (0.95 to 2.23)    0.081                                 
  Matsanjeni                  95 (33.9)                                                                     40 (32.8)                        1.30 (0.83 to 2.04)    0.243                                 
  EAC                                                                                                                                                                                                     
  Zero sessions               72 (25.6)                                                                     26 (21.0)                        Reference              \_\_        Reference                 \_\_
  One session                 44 (15.9)                                                                     21 (17.7)                        1.25 (0.71 to 2.18)    0.436       1.22 (0.66 to 2.23)       0.523
  Two sessions                58 (20.9)                                                                     26 (21.8)                        1.62 (0.95 to 2.76)    0.077       1.69 (0.93 to 3.09)       0.087
  Three sessions              104 (37.6)                                                                    47 (39.5)                        1.31 (0.82 to 2.10)    0.263       1.30 (0.77 to 2.19)       0.322
  Treatment outcome                                                                                                                                                                                       
  Retained in care            202 (72.6)                                                                    120 (100)                                                                                     
  LTFU                        76 (27.4)                                                                     0 (0)                                                                                         
  Genotype                                                                                                                                                                                                
  No genotype                 205 (73.6)                                                                    77 (63.9)                                                                                     
  Genotype done               73 (26.4)                                                                     43 (36.1)                                                                                     
  Successful genotype                                                                                                                                                                                     
  No result                   220 (79.1)                                                                    83 (68.9)                                                                                     
  Genotype result available   58 (20.9)                                                                     37 (31.1)                                                                                     
  Time on ART                 3.15 years (IQR: 1.95, 4.69)                                                  3.26 years (IQR: 2.27, 4.79)     1 (0.99 to 1.00)       0.181                                 

ABC, abacavir; ART, antiretroviral therapy; aSHR, adjusted subdistribution hazard ratio; AZT, zidovudine; cSHR, crude subdistribution hazard ratio; D4T, stavudine; EAC, enhanced adherence counselling; EFV, efavirenz; IQR, interquartile range; LTFU, lost to follow‐up; NRTI, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; TDF, tenofovir; VL, viral load.
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Treatment switching remained low (43.0% at the end of follow‐up), higher compared with the early rollout [23](#jia225194-bib-0023){ref-type="ref"} and comparable to other studies [41](#jia225194-bib-0041){ref-type="ref"}, [42](#jia225194-bib-0042){ref-type="ref"}. In this setting, clinicians are instructed to switch at time of virological failure but delayed treatment switching. Without irrefutable evidence of the ineffectiveness of the current treatment, clinicians may aim for conservation of treatment options when therapeutic options are limited [30](#jia225194-bib-0030){ref-type="ref"}, [43](#jia225194-bib-0043){ref-type="ref"}.

The cascade is illustrated in Figure [1](#jia225194-fig-0001){ref-type="fig"}. The disengagement from care between the first and second VL tests and between the second elevated VL and treatment switching is of concern as it may contribute to increased mortality and onward transmission [44](#jia225194-bib-0044){ref-type="ref"}, [45](#jia225194-bib-0045){ref-type="ref"}, [46](#jia225194-bib-0046){ref-type="ref"}.

![The viral load and treatment switching cascade.\
EAC, enhanced adherence counselling; LFTU, lost to follow‐up; VL, viral load.](JIA2-21-e25194-g001){#jia225194-fig-0001}

3.6. HIV drug resistance testing {#jia225194-sec-0020}
--------------------------------

In total, 214 DBS samples were collected from adults with virological failure in primary and secondary care facilities. Of these, 155 (72.4%) were successfully sequenced, with 144 (92.9%) patients on first‐line ART, 10 (6.5%) on second‐line ART and 1 (0.6%) missing regimen information. Ninety‐three (60.0%) patients were female, sixty (38.7%) were male and two (1.3%) had missing sex information. Sixty‐seven (43.2%) patients were from primary care clinics, seventy‐nine (51.0%) were from secondary care facilities and nine (5.8%) had missing health facility information. Resistance to both EFV and NVP ranged from 87.5% to 100% by regimen (*p *=* *0.881), and resistance to LPV/r ranged from 0% to 66.7% by regimen (*p *=* *0.054) (Table [3](#jia225194-tbl-0003){ref-type="table"}).

###### 

DR by antiretroviral therapy regimen

            First line, n (%)   *p* value     Second line, n (%)   *p* value                                                                                                         
  --------- ------------------- ------------- -------------------- ------------- ------------- ------------- ------------- --------- --------------- --------------- --------------- -------
  Regimen   AZT/3TC/NVP         AZT/3TC/EFV   TDF/3TC/NVP          TDF/3TC/EFV   D4T/3TC/NVP   D4T/3TC/EFV   ABC/3TC/EFV             ABC/DDI/LPV/r   AZT/3TC/LPV/r   TDF/3TC/LPV/r   
  Total     59                  26            13                   40            3             2             1             144       3               3               4               10
  AZT       44 (74.6)           13 (50.0)     5 (38.5)             7 (17.5)      2 (66.7)      1 (50)        0 (0)         \<0.001   1 (33.3)        0 (0)           2 (50.0)        0.356
  3TC       55 (93.2)           23 (88.5)     12 (92.3)            34 (85)       3 (100)       2 (100)       1 (100)       0.851     2 (66.7)        2 (66.7)        3 (75.0)        0.961
  TDF       29 (49.2)           12 (46.2)     7 (53.8)             31 (77.5)     1 (33.3)      2 (100)       0 (0)         0.041     2 (66.7)        2 (66.7)        1 (25.0)        0.435
  ABC       55 (93.2)           23 (88.5)     12 (92.3)            34 (85)       3 (100)       2 (100)       1 (100)       0.851     2 (66.7)        2 (66.7)        3 (75.0)        0.961
  D4T       42 (71.2)           15 (57.7)     9 (69.2)             31 (77.5)     2 (66.7)      2 (100)       0 (0)         0.400     1 (33.3)        1 (33.3)        2 (50.0)        0.87
  DDI       44 (74.6)           18 (69.2)     9 (69.2)             33 (82.5)     2 (66.7)      2 (100)       1 (100)       0.805     2 (66.7)        2 (66.7)        2 (50.0)        0.87
  NVP       56 (94.9)           24 (92.3)     12 (92.3)            35 (87.5)     3 (100)       2 (100)       1 (100)       0.881     2 (66.7)        2 (66.7)        3 (75.0)        0.961
  EFV       56 (94.9)           24 (92.3)     12 (92.3)            35 (87.5)     3 (100)       2 (100)       1 (100)       0.881     2 (66.7)        2 (66.7)        3 (75.0)        0.961
  LPV/r     1 (1.7)             0 (0)         0 (0)                0 (0)         0 (0)         0 (0)         0 (0)         0.963     2 (66.7)        0 (0)           0 (0)           0.054

3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; DR, drug resistance; EFV, efavirenz; LPV/r, ritonavir‐boosted lopinavir; NVP, nevirapine; TDF, tenofovir.
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The WHO algorithm accurately predicted resistance requiring a switch to second‐line therapy. Of the 144 first‐line patients, 133 (92.4%) had low, intermediate or high resistance to both EFV and NVP and were eligible for switching to second‐line ART (PPV for the need for treatment switching). This equated to 61 (95.3%) of 64 patients from primary health clinics and 63 (88.7%) of 71 patients from secondary health facilities. Only two (20%) of the second‐line patients had resistance to LPV/r.

The WHO algorithm had high accuracy for predicting failure of first‐line ART as also reported from other sub‐Saharan settings, where resistance ranged from 53% to 93% [47](#jia225194-bib-0047){ref-type="ref"}, [48](#jia225194-bib-0048){ref-type="ref"}, [49](#jia225194-bib-0049){ref-type="ref"}, [50](#jia225194-bib-0050){ref-type="ref"}. Following a public health approach, patients failing first‐line regimens do not need DR testing for confirmation of treatment failure before treatment switching. This algorithm, however, showed a low PPV for patients on second‐line therapy (20%), therefore requiring HIV DR testing to avoid premature switches to third‐line ART. Other studies also showed that a minority of patients with virological failure had PI DR levels requiring treatment switching [39](#jia225194-bib-0039){ref-type="ref"}, [51](#jia225194-bib-0051){ref-type="ref"}.

This study had several limitations. The use of routine data is prone to suboptimal data quality and completeness, and leakages in our cascade might bias our findings. We could not ascertain patients' final outcome and differentiate between patients LTFU and deceased. Because of the small number of second‐line patients, any significant associations for this group should be interpreted with caution.

4. Conclusions {#jia225194-sec-0021}
==============

VL monitoring has the potential to improve ART programmes and to bolster treatment support. We showed that the WHO VL algorithm works well for patients on first‐line ART. However, the ramifications of any delay are serious given the number of patients LTFU between each cascade step. Finally, for patients with suspected virological failure, even in the face of ongoing adherence problems, treatment switching should be considered as our data show that they most likely do have resistant mutations.
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